Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE: Pulmonary Embolism & Anticoagulation Evaluation in Cancer Patients
2025-524110-28-00Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Jun 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of edoxaban, dalteparin, tinzaparin, apixaban, enoxaparin and 1 more in pulmonary embolism (PE), venous thromboembolism (VTE) and cancer-associated thrombosis (CAT) (2 arms), sponsored by Capital Region of Denmark. Primary endpoint: Primary composite hierarchical endpoint (WIN ratio). Planned start Jun 2026; status: authorised.
02
Drugs
edoxabandalteparintinzaparinapixabanenoxaparin
03
Conditions
pulmonary embolism (PE)venous thromboembolism (VTE)cancer-associated thrombosis (CAT)
Beyond the preview
Go deeper on 2025-524110-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524110-28-00.